VIVES is a multi-sector fund that invests in projects with a positive societal impact
Sleep disorders affect over 2 billion people worldwide, with 1 billion suffering from obstructive sleep apnea, a condition linked to serious health issues such as hypertension, diabetes, and...
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation biologics for severe immune-mediated inflammatory diseases. Bionyra’s best-in-class mono and multispecific...
The Akkermansia company is the first co-spin-off resulting from joint research conducted at two European universities, the Catholic University of Louvain (BE) and the University of Wageningen (NL). It...
Pierre Delatte, CTO and co-founder of Cissoid:
"With the VIVES fund, we have found a partner who understands the challenge of bringing technology from a university laboratory to the commercialization...
Philippe Mengal, past CEO Greenwatt:
"The support of VIVES was essential because it was first of all a demonstration of confidence at a very early stage of the company just out of UCL Laboratories...
Chris Buyse, co-founder and Managing Partner of Fund+:
"Fund+ is impressed by the outstanding scientific achievements of our Belgian universities and therefore supports and invests in its innovative...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to